Patents by Inventor Steven L. Wagner

Steven L. Wagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11117884
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: September 14, 2021
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Publication number: 20200055840
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A? peptide levels, including Alzheimer's disease.
    Type: Application
    Filed: October 25, 2019
    Publication date: February 20, 2020
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Patent number: 10472346
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 12, 2019
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Patent number: 9938263
    Abstract: There are provided, inner alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 10, 2018
    Assignees: The General Hospital Corporation, The Regents of the University of California
    Inventors: Rudolph E. Tanzi, Steven L. Wagner, Soan Cheng, William C. Mobley
  • Publication number: 20180093967
    Abstract: Provided herein are compounds and methods for treating a disorder associated with aberrant A3 peptide levels, including Alzheimer's disease. Provided herein are compositions and methods for treating a disorder associated with aberrant A? peptide levels, including AD. Provided herein are compounds of Formula (A) or a pharmaceutically acceptable salt thereof, wherein, L? is selected from the group consisting of C(O), C(R1)(R2), substituted or unsubstituted —C2-6 alkylene-, and substituted or unsubstituted —C3-6 cycloalkylene.
    Type: Application
    Filed: October 30, 2015
    Publication date: April 5, 2018
    Inventors: Steven L. Wagner, William C. Mobley, Rudolph E. Tanzi, Graham Johnson, Ronald Buckle, Nicholas Mayhew, Robert Jason Herr, Kevin D. Rynearson
  • Patent number: 9403815
    Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)-(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: August 2, 2016
    Assignees: The Regents of the University of California, The General Hospital Corporation
    Inventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
  • Publication number: 20160024073
    Abstract: There are provided, imer alia, compounds and methods for lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase. Since all of the major AB peptide variants, including the pathogenic AB42 as known in the art, are ultimately generated by gamma-secretase-mediated proteolysis of APP-C99 (i.e., the beta-secretase-mediated cleavage product of the amyloid protein precursor IAPPI), one approach to therapeutic intervention (e.g., intervention in Alzheimer's Disease, AD) relates to lowering total AB peptide production by inhibiting the catalytic activity of gamma-secretase.
    Type: Application
    Filed: March 12, 2014
    Publication date: January 28, 2016
    Inventors: Rudolph E. TANZI, Steven L. WAGNER, Soan CHENG, William C. MOBLEY
  • Publication number: 20130165416
    Abstract: The invention provides a novel compound having a structure corresponding to Formula (I): (A)-(B)—(C)-(D)??(I) or a pharmaceutically acceptable salt or prodrug thereof and methods for using them.
    Type: Application
    Filed: June 24, 2011
    Publication date: June 27, 2013
    Inventors: Steven L. Wagner, Soan Cheng, William C. Mobley, Rudolph E. Tanzi
  • Publication number: 20020177120
    Abstract: Recombinant cells expressing fluorescence resonance energy transfer reporter polypeptides and cell-based assays for apoptosis; screening assays for identifying and selecting candidate compounds modulating apoptosis.
    Type: Application
    Filed: June 4, 1999
    Publication date: November 28, 2002
    Inventors: KATHRYN J. ELLIOTT, MARIA Z. KOUNNAS, REBECCA J. DYER, BENITO MUNOZ, STEVEN L. WAGNER
  • Patent number: 5600565
    Abstract: Each item a system or order group carries a label having, in addition to a predetermined primary code denoting its item type, another, secondary, code representing a random identifier for that individual item. When a system or order group is to be packaged, a worker selects each item according to a list, scans its label, and physically places the item with the order group. The predetermined primary and random secondary codes are compared with those of previous items in the same order group. A complete match with the codes of another item in the same group causes the item to be rejected.
    Type: Grant
    Filed: December 22, 1994
    Date of Patent: February 4, 1997
    Assignee: International Business Machines Corporation
    Inventors: Steven L. Wagner, Stephen E. Wheeler
  • Patent number: 5427931
    Abstract: Monoclonal antibody and the hybridoma producing the antibody are disclosed. The antibody is produced against an epitope on native secreted forms of .beta.APP. A characteristic of the antibody is that the antibody specifically binds to at least one protein in culture medium in which neuroblastoma cells have been grown. This protein co-migrates in non-reducing polyacrylamide gel electrophoresis with PN-2 isolated from human fibroblast cultures. Other characteristics of the antibody are that the antibody specifically binds to PN-2 and to the secreted form of .beta.APP lacking the Kunitz-type inhibitor domain, the antibody selectively binds to neuritic plaques, and the antibody is sufficiently sensitive to detect secreted forms of .beta.APP in CSF, down to a total concentration of the secreted forms of .beta.APP of 3.75 .mu.g/ml or lower.
    Type: Grant
    Filed: April 27, 1993
    Date of Patent: June 27, 1995
    Assignee: Then Regents of the University of California
    Inventors: William E. Van Nostrand, Dennis D. Cunningham, Steven L. Wagner
  • Patent number: 5270165
    Abstract: A method of diagnosing a disease with cerebrovascular deposition of amyloid, including Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis-Dutch type and other amyloidoses, in a mammal is disclosed in which a sample of cerebrospinal fluid is obtained, the level of immunoreactivity toward a monoclonal antibody raised against native PN-2/.beta.APP or other amyloid precursor protein in the sample is measured, and this measured level is compared to the level of immunoreactivity toward this antibody in a sample fromNOTICE OF GOVERNMENT SUPPORTThis invention was made with Government support under Grant No. GM-31609 awarded by the National Institutes of Health. The Government has certain rights in this invention. American Cancer Society Grants CD 390 and BC 602/BE 22A provided further support for the development of this invention.
    Type: Grant
    Filed: October 15, 1991
    Date of Patent: December 14, 1993
    Assignee: The Reagents of the University of California
    Inventors: William E. Van Nostrand, Dennis D. Cunningham, Steven L. Wagner
  • Patent number: 5213962
    Abstract: Immunopurification of Protease Nexin-2 and .beta. amyloid precursor protein is disclosed. Methods of detecting Protease Nexin-2 and the use of these methods in the diagnosis of Alzheimer's disease and other conditions are also disclosed. Additionally, pharmaceutical preparations including Protease Nexin-2 or modified forms thereof are disclosed. Medical uses for the pharmaceutical preparations are also disclosed.
    Type: Grant
    Filed: July 30, 1992
    Date of Patent: May 25, 1993
    Assignee: The Regents of the University of California
    Inventors: William E. Van Nostrand, Dennis D. Cunningham, Steven L. Wagner
  • Patent number: 5134076
    Abstract: Monoclonal antibodies having a specificity for protease nexin-1 are described. Preferably an antibody has specificity to the reactive protease-binding site. The antibody is used in the affinity purification of PN-1 to produce large quantities of substantially pure PN-1, free of other biologically active molecules. Over a 2000-fold purification of a crude preparation of PN-1 may be obtained. The affinity-purified PN-1 is suitable for use in pharmacological preparations used in the treatment of neurological disease associated with serine protease-mediated inhibition of regenerative processes.
    Type: Grant
    Filed: September 27, 1988
    Date of Patent: July 28, 1992
    Assignee: The Regents of the University of California
    Inventors: Dennis D. Cunningham, Steven L. Wagner, William E. Van Nostrand